Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up

This presentation utilizes an indirect treatment comparison with an extended follow-up to evaluate the long-term clinical efficacy of the next-generation BTK inhibitor zanubrutinib against older targeted therapies for previously untreated chronic lymphocytic leukemia. The findings suggest that zanubrutinib provides a progressively durable survival and progression-free advantage over both ibrutinib and acalabrutinib, with therapeutic benefits becoming more pronounced over time. These long-term outcomes help differentiate the clinical profiles of these frontline therapies and can provide valuable guidance for oncology decision-making in the absence of direct head-to-head clinical trials.